Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) and Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.
Analyst Recommendations
This is a summary of current ratings and target prices for Soleno Therapeutics and Akebia Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Soleno Therapeutics | 1 | 9 | 3 | 0 | 2.15 |
| Akebia Therapeutics | 1 | 1 | 3 | 0 | 2.40 |
Soleno Therapeutics presently has a consensus target price of $76.67, suggesting a potential upside of 45.01%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 233.33%. Given Akebia Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Soleno Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Soleno Therapeutics | $190.40 million | 14.33 | $20.89 million | $0.23 | 229.87 |
| Akebia Therapeutics | $236.20 million | 1.59 | -$5.34 million | ($0.02) | -70.00 |
Soleno Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Soleno Therapeutics has a beta of -2.22, indicating that its stock price is 322% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.
Institutional and Insider Ownership
97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Soleno Therapeutics and Akebia Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Soleno Therapeutics | N/A | 5.90% | 4.61% |
| Akebia Therapeutics | -2.26% | -16.70% | -1.53% |
Summary
Soleno Therapeutics beats Akebia Therapeutics on 9 of the 13 factors compared between the two stocks.
About Soleno Therapeutics
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
